Blueprint Medicines Corporation

NasdaqGS BPMC

Blueprint Medicines Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -55.35%

Blueprint Medicines Corporation EBITDA Margin is -55.35% for the Trailing 12 Months (TTM) ending September 30, 2024, a 75.11% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Blueprint Medicines Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was -222.41%, a 12.26% change year over year.
Blueprint Medicines Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -253.48%, a 32.71% change year over year.
Blueprint Medicines Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -376.70%, a -1,009.04% change year over year.
Blueprint Medicines Corporation EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 41.44%, a 101.81% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: BPMC

Blueprint Medicines Corporation

CEO	Ms. Kathryn Haviland M.B.A.
IPO Date	April 30, 2015
Location	United States
Headquarters	45 Sidney Street
Employees	638
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years